Home > Cardiology > HFA 2022 > DAPA-VO2: Rapid effect of dapagliflozin on Peak VO2 in stable HFrEF

DAPA-VO2: Rapid effect of dapagliflozin on Peak VO2 in stable HFrEF

Presented By
Dr Julio Núñez, University of Valencia, Spain
Conference
HFA 2022
Trial
DAPA-VO2
Patients with stable heart failure with reduced ejection fraction (HFrEF) who were treated with dapagliflozin displayed a positive significant effect on peakVO2 already after 1 month of treatment, an effect that lasted for at least 3 months. This was the main primary result of the DAPA-VO2 trial [1]. Dapagliflozin has been demonstrated to decrease clinical events in patients with stable HFrEF and recent data suggests that also early clinical benefits may be expected with this therapy [2]. To assess whether dapagliflozin indeed offers such early benefits for patients, Dr Julio Núñez (University of Valencia, Spain) and co-investigators designed the multicentre, randomised DAPA-VO2 trial (NCT04197635). In this study, 90 patients with stable HFrEF were randomised 1:1 to placebo or dapagliflozin in addition to guideline-directed medical therapy. The primary endpoint was...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on